CRM
Salesforce, Inc.
CRM has the edge over JPM overall, supported by stronger valuation and stronger fundamentals.
JPM
JPMorgan Chase & Co.
JPM has lower modeled downside risk, despite its lower overall score.
CRM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Stable |
CRM's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
CRM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 20x | $218 | — |
| Cheap | 36x | $393 | +80% |
| Fair | 70x | $766 | +252% |
| Expensive | 293x | $3,206 | +1374% |
Historical ranges are pointers, not guarantees.
CRM has the edge over JPM in the historical PE scenario, which offers more potential upside but is not a forecast.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM's PE is in its expensive range at 14.4x. If earnings grow as analysts expect, today's price would be 13.7x next year's earnings.
CRM Forward outlook
There aren't enough analyst estimates for CRM to show an outlook.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JPM, with profitability improving.
CRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $10.96 | +59% |
| Q2 2026 | $8.63 | +35% |
| Q1 2026 | $7.80 | +23% |
| Q4 2025 | $7.49 | +23% |
| Q3 2025 | $6.88 | +20% |
| Q2 2025 | $6.39 | +15% |
| Q1 2025 | $6.36 | +51% |
| Q4 2024 | $6.08 | +131% |
CRM has the edge over JPM on earnings, with stronger typical year-over-year growth.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM's earnings per share have climbed steadily: $23.85 over the past year, up 18% from the year before, and higher year over year for 15 quarters in a row.
CRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.3B | +11% |
| Q2 2026 | $11.1B | +13% |
| Q1 2026 | $11.2B | +12% |
| Q4 2025 | $10.3B | +8.6% |
| Q3 2025 | $10.2B | +9.8% |
| Q2 2025 | $9.8B | +7.6% |
| Q1 2025 | $10B | +7.6% |
| Q4 2024 | $9.4B | +8.3% |
CRM has the edge over JPM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | -2.2 points |
| Q2 2026 | 21% | +1.3 points |
| Q1 2026 | 17% | -1.5 points |
| Q4 2025 | 21% | +1.3 points |
| Q3 2025 | 23% | +3.7 points |
| Q2 2025 | 20% | +1.1 points |
| Q1 2025 | 18% | +0.7 points |
| Q4 2024 | 20% | +2.8 points |
CRM's operating margin was 21% last quarter, down 2.2 points from the same quarter a year ago.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM's revenue has grown year over year for five quarters in a row: $50.2B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM has the edge over CRM on profitability, with a higher operating margin.
CRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +81% |
| Q2 2026 | $6.6B | +4.1% |
| Q1 2026 | $5.3B | +39% |
| Q4 2025 | $2.2B | +22% |
| Q3 2025 | $605M | -20% |
| Q2 2025 | $6.3B | +3.5% |
| Q1 2025 | $3.8B | +17% |
| Q4 2024 | $1.8B | +30% |
CRM has the edge over JPM on cash generation, producing positive trailing cash flow while its opponent burns cash.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
CRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.5x | Moderate |
| Q2 2026 | 2.4x | Moderate |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.0x | Net Cash |
| Q4 2024 | 0.0x | Very low |
CRM's net debt is about 2.5 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM has the edge over CRM on leverage, with a lower net debt burden relative to earnings.
CRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.7 | Neutral |
| Stochastic | 44.2 | Neutral |
CRM's weekly RSI is 51 (neutral) and its Stochastic is 44 (neutral).
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
CRM PE vs Technology Sector
| Metric | CRM | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 28x | 29% below |
| PE % | 2 | 35 | 33 pts below |
CRM has the edge over JPM on valuation relative to its sector.
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM is trading at 14x earnings, a 10% premium to the Financial Services sector's median of 13x.
CRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $230.9 | 5.8% below |
| 20 week MA | $214.7 | 1.3% above |
| 50 week MA | $206.8 | 5.2% above |
| 100 week MA | $239.7 | 9.2% below |
| 200 week MA | $242.0 | 10% below |
CRM's trend is mixed: it's above two of its five weekly moving averages, and 10% below its 200-week average.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM has the edge over CRM on trend strength, trading above more of its moving averages.
CRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $165.0 | $225.8 | +37% |
| 2021 | $225.8 | $253.1 | +12% |
| 2022 | $253.1 | $129.4 | -49% |
| 2023 | $129.4 | $263.1 | +103% |
| 2024 | $263.1 | $338.5 | +29% |
| 2025 | $338.5 | $266.1 | -21% |
| 2026 YTD | $266.1 | $217.6 | -18% |
CRM's yearly returns have swung widely, from +103% in 2023 to −49% in 2022. It's down 18% so far in 2026.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has the edge over CRM on returns for 2026, with the stronger performance.